Drug-induced liver disease

Diseases of the Liver and Biliary System in Children: Third Edition

Volumn , Issue , 2009, Pages 207-230

  Murray, Karen F ^a  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889828133     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300536.ch9     Document Type: Chapter

References (206)

1. Farrell GC, Liddle C. Drugs and the liver updated, 2002. Semin Liver Dis 2002;22:109-13.
2. Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-8.
3. Ravikumara M, Hill FG, Wilson's DC, et al. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia-a dual-centre experience. J Pediatr Gastroenterol Nutr 2006;42:535-8.
4. Mahadevan SB, McKiernan PJ, Davies P, Kelly DA. Acetaminophen induced hepatotoxicity. Arch Dis Child 2006;91:598-603.
5. Murray KF, Messner DJ, Kowdley KV. Mechanism of hepatocyte detoxification. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract, 4th ed. Burlington, MA: Elsevier Academic Press, 2006: 1483-504.
6. Bromer MW, Black M. Acetaminophen hepatoxicity. Clin Liver Dis 2003;7:351-67.
7. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997;130:300-4.
8. Lauterburg BH, Vaishnav Y, Stillwell WG, Mitchell JR. The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther 1980;213:54-8.
9. Morgan O, Majeed A. Restricting acetaminophen in the United Kingdom to reduce poisoning: a systematic review. J Public Health (Oxf) 2005;27:12-8.
10. Hawton K, Simkin S, Deeks J, et al. UK legislation on analgesic packs: before and after study of long term effect on poisonings. BMJ 2004;329:1076.
11. Rumack BH. Acetaminophen overdose in children and adolescents. Pediatr Clin N Am 1986;33:691-701.
12. Heubi JE. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. J Pediatr Gastroenterol Nutr 2007;44:513-5.
13. Sztajnkerycer MJ, Bond GR. Chronic acetaminophen overdosing in children: risk assessment and management. Curr Opin Pediatr 2001;13:177-82.
14. Kozer E, Koren G. Management of acetaminophen overdose: current controversies. Drug Saf 2001;24:503-12.
15. Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr 2005;40:575-81.
16. Teoh NC, Farrell GC. Hepatotoxicity associated with nonsteroidal anti-inflammatory drugs. Clin Liver Dis 2003;7:401-13.
17. Voigt MD, Workman B, Lombard C, Kirsch RE. Halothane hepatitis in a South African population-frequency and the influence of gender and ethnicity. S Afr Med J 1997;87:882-5.
18. Weber P, Scheurlen M, Irkin I, et al. [Liver transplantation in halothane-induced liver necrosis; in German.] Zentralbl Chir 1994;119:305-8.
19. Wark HJ. Postoperative jaundice in children. The influence of halothane. Anaesthesia 1983;38:237-42.
20. Pratilas V, Pratila MG. Multiple halothane anesthesias in a child: a case report. Mt Sinai J Med 1978;45:480-3.
21. Hassall E, Israel DM, Gunasekaran T, Steward D. Halothane hepatitis in children. J Pediatr Gastroenterol Nutr 1990;11:553-7.
22. Kenna JG, Neuberger J, Mieli-Vergani G, Mowat AP, Williams R. Halothane hepatitis in children. Br Med J (Clin Res Ed) 1987; 294:1209-11.
23. Lo SK, Wendon J, Mieli-Vergani G, Williams R. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol 1998;10:635-9.
24. Committee on Safety of Medicines. Current Problems. London: Committee on Safety of Medicines, 1986.
25. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347:1367-71.
26. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996;50: 573-82.
27. Bourdi M, Chen W, Peter RM, et al. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-66.
28. Njoku D, Laster MJ, Gong DH, Eger EI 2nd, Reed GF, Martin JL. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997;84:173-8.
29. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30.
30. Fernández-Villar A, Sopeña B, Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004;8:1499-505.
31. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-6.
32. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-6.
33. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
34. [No authors listed.] National American College of Chest Physicians consensus conference on tuberculosis. Chest 1985; 87(2 Suppl):115S-149S.
35. Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculosis chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002;72:220-6.
36. Brummer DL. Isoniazid and liver disease. Ann Intern Med 1971; 75:643-4.
37. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-7.
38. Larson AM, Graziani AL. Isoniazid Hepatoxicity. In: Up to Date, Rose, BD, ed., 2007; Up to Date, Wellesley, MA.
39. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
40. Kopanoff DE, Sinder DE, Caras GH. Isoniazid-related hepatitis A. U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001.
41. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin-a meta-analysis. Chest 1991;99:465-71.
42. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71:113-20.
43. Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated hepatitis-New York, 1991-1993. MMWR Morb Mortal Wkly Rep 1993;42:545-7.
44. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Liver physiology and disease: isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
45. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79:1-12.
46. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978; 59:13-32.
47. Bass NM, Ockner RK. Drug-induced liver disease. In: Zakim D, Boyer TD, eds. Hepatopathology. Philadelphia: Saunders, 1996: 962-1017.
48. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145: 494-7.
49. Cohen R, Kalser MH, Thompson RV. Fatal hepatic necrosis secondary to isoniazid therapy. JAMA 1961;176:877-9.
50. Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994;39:2255-9.
51. Cillo U, Bassanello M, Vitale A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. Transpl Int 2005;17:713-6.
52. Vanderhoof JA, Ament ME. Fatal hepatic necrosis due to isoniazid chemoprophylaxis in a 15-year-old girl. J Pediatr 1976;88:867-8.
53. Berkowitz FE, Henderson SL, Fajman N, Schoen B, Naughton M. Acute liver failure caused by isoniazid in a child receiving carbamazepine. Int J Tuberc Lung Dis 1998;2:603-6.
54. Casteels-Van Daele M, Igodt-Ameye L, Corbeel L, Eeckels R. Hepatoxicity of rifampicin and isoniazid in children. J Pediatr 1975;86:739-41.
55. Hasagawa T, Reyes J, Nour B, et al. Successful liver transplantation for isoniazid-induced hepatic failure-a case report. Transplantation 1994;57:1274-7.
56. Raleigh JW. Rifampin in treatment of advanced pulmonary tuberculosis. Report of a VA cooperative pilot study. Am Rev Respir Dis 1972;105:397-409.
57. Lees AW, Allan GW, Smith J. Toxicity from rifampin plus isoniazid and rifampin plus ethambutol therapy. Tubercle 1971; 52:182-90.
58. Kenwright S, Levi AJ. Sites of competition in the selective hepatic uptake of rifampicin-SV, flavaspidic acid, bilirubin, and bromsulphthalein. Gut 1974;15:220-6.
59. Mulder DJ, Mulder RJ. Drugs used in the treatment of tuberculosis and leprosy. In: Dukes MUG, ed. Meyler's Side Effects of Drugs. Oxford: Excerpta Medica, 1977: 676-89.
60. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7.
61. Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9.
62. Westphal JF, Brogard JM. Antibacterials and antifungal agents. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. New York: Marcel-Dekker, 2003: 471-504.
63. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992;15:154-61.
64. Parry MF. The penicillins. Med Clin North Am 1987;71:1093-112.
65. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxi-cillin and clavulanic acid. Arch Intern Med 1996;156:1327-32.
66. Anderson CS, Nicholls J, Rowland R, LaBrooy JT. Hepatic granulomas: a 15-year experience in the Royal Adelaide Hospital. Med J Aust 1988;148:71-4.
67. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of the bile ducts, red cell aplasia and the Stevens-Johnson syndrome: an ampicillin-associated case. Gastroenterology 1990;99: 854-6.
68. Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. An unusual case of amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol 1998;93:1363-5.
69. Stiegbauer KT, Smith C, Snoyer DC. The histological features of amoxicillin/clavulanic acid-induced hepatotoxicity. Hepatology 1994;20:190A.
70. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992;33:368-71.
71. Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994;20:112-6.
72. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 2001;6:139-49.
73. Chawla A, Kahn E, Yunis EJ, Daum F. Rapidly progressive cholestasis: an unusual reaction to amoxicillin/clavulanic acid therapy in a child. J Pediatr 2000;136:121-3.
74. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995;23:278-82.
75. Hautekeete ML, Brenard R, Horsmans Y, et al. Liver injury related to amoxicillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995;22:71-7.
76. Mollison LC, Angus P, Richards M, Jones RM, Ireton J. Hepatitis due to nitrofurantoin. Med J Aust 1992;156:347-9.
77. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-6.
78. George DK, Crawford DH. Antibacterial-induced hepatotoxi-city. Incidence, prevention and management. Drug Saf 1996; 15: 79-85.
79. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993;158:596-600.
80. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin-associated jaundice. BMJ 1993;306: 233-5.
81. Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin-induced delayed cholestatic hepatitis. Aust N Z J Med 1990;20:251-3.
82. Easton-Carter KL, Hardikar W, Smith AL. Possible roxithromycin-induced fulminant hepatic failure in a child. Pharmacotherapy 2001;21:867-70.
83. Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989;151:701-5.
84. Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillins and ureidopeni-cillins. Rev Infect Dis 1991;13:68-72.
85. Thompson JW, Jacobs RF. Adverse effects of newer cephalo-sporins: an update. Drug Saf 1993;9:132-42.
86. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990;88(Suppl 4A):38S-44S.
87. Kiessling S, Forrest K, Moscow J, et al. Interstitial nephritis, hepatic failure, and systemic eosinophilia after minocycline treatment. Am J Kidney Dis 2001;38:E36.
88. Fréneaux E, Labbe G, Letteron P, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988;8:1056-62.
89. Combes B, Whalley PJ, Adams RH. Tetracycline and the liver. Prog Liver Dis 1972;4:589-96.
90. Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000;95:560-1.
91. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994;107:1844-7.
92. Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 1989;298:1523-4.
93. Min DI, Burke PA, Lewis WD, Jenkins RL. Acute hepatic failure associated with oral minocycline: a case report. Pharmacotherapy 1992;12:68-71.
94. Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD. The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 2001;41:852-60.
95. Bhat G, Jordan J Jr, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998;27: 74-5.
96. Chamberlain MC, Schwarzenberg SJ, Akin EU, Kurth MH. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr 2006;42:232-5.
97. Carson JL, Strom BL, Duff A, et al. Acute liver disease with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993;119:576-83.
98. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993;158:600-2.
99. Avila P, Capellà D, Laporte JR, Moreno V. Which salt of erythromycin is most hepatotoxic? Lancet 1988;i:1104.
100. Young RA, Gonzales JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989;37:8-41.
101. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-64.
102. Yew WW, Chau CH, Lee J, Leung CW. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection [letter]. Clin Infect Dis 1994;18:1025-6.
103. Dujovne CA. Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol 1978;27:1925-30.
104. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985;16(Suppl A):181-94.
105. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1973;119: 300-6.
106. Diehl AM, Latham P, Boitnott JK, Mann J, Maddrey WC. Cholestatic hepatitis from erythromycin ethylsuccinate. Am J Med 1984;76:931-4.
107. Zimmerman HJ, Maddrey WC. Drug-induced hepatotoxicity. In: Schiff L, Schiff ER, eds. Diseases of the Liver. Philadelphia: Lippincott, 1987: 707-783.
108. Zhang XJ, Thomas PE. Erythromycin as a specific substrate for cytochrome P450 3A isoenzymes and identification of a high affinity erythromycin N-demethylase in adult female rats. Drug Metab Dispos 1996;24:23-7.
109. Larrey D, Funck-Brentano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983;32:1063-8.
110. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979;24:385-96.
111. Gholson CF, Warren CH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990;150:215-6.
112. Farrell GC. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone, 1994.
113. Beard K, Belic L, Aselton P, Perera DR, Jick H. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986;26:633-7.
114. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
115. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988;109:280-7.
116. Droge W. Cysteine and glutathione deficiency in AIDS patients: a rationale for the treatment with V-acetylcysteine. Pharmacology 1993;46:61-5.
117. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994;11:196-212.
118. Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. V Engl J Med 1967;277:785-8.
119. Fatal multisystemic toxicity after co-trimoxazole. Lancet 1978;i: 831.
120. Colucci CF, Cicero ML. Hepatic necrosis and trimethoprim-sulfamethoxazole. JAMA 1975;233:952-3.
121. Tonder M, Nordoy A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974;9:93-6.
122. Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med 1985;102:722.
123. Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978;71: 1159-60.
124. Steward DL, Johnson RC. Acute hepatitis caused by sulfamethoxazole-trimethoprim. Gastroenterology 1980;78:1323.
125. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim-sulfamethoxazole. Gastroenterology 1992;102: 2148-50.
126. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology 1981;80:816-9.
127. Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis: inadvertent rechallenge. Arch Intern Med 1984;144:1691-2.
128. Schacht P, Hullmann R. Safety of oral ciprofloxacin: an update based on clinical trial results. Am J Med 1989;87(Suppl 5A): 98S-102S.
129. Jick SS, Jick HJ, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993;13:461-4.
130. Arcieri GM, Becker N, Esposito B, et al. Safety of intravenous ciprofloxacin: a review. Am J Med 1989;87(Suppl 5A):92S-97S.
131. Fuchs S, Simon Z, Brezin M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994;343:738-9.
132. Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26:636-9.
133. Dembry LM, Farrington JM, Andriole VT. Fluoroquinolone antibiotics: adverse effects and safety profile. Infect Dis Clin Pract 1999;8:421-8.
134. Stricker BH. Drug-Induced Hepatic Injury, 2nd ed. Amsterdam: Elsevier, 1992.
135. Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972;263:369-82.
136. Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med 1974;57:627-30.
137. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sufamethoxazole. Am J Gastroenterol 1994;89:1230-4.
138. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52.
139. Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986;3:399-406.
140. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management. Drug Saf 1992;7:323-63.
141. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7.
142. Rollman O, Loof L. Hepatic toxicity of ketoconazole. Br J Dermatol 1983;143:376-8.
143. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ 1987;294:419-22.
144. Zollner E, Delport S, Bonnici F. Fatal liver failure due to keto-conazole treatment of a girl with Cushing's syndrome. J Pediatr Endocrinol 2001;14:335-8.
145. Findor JA, Sorda JA, Igartua EB, Avagnina A. Ketoconazole-induced liver damage. Medicina 1998;58:277-81.
146. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999;33:683-5.
147. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
148. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984;131:1245-47.
149. Grant SM, Clissold SP. Itraconazole. A review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
150. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.
151. Srebrnik A, Levtov S, Ben-Ami R, Brenner S. Liver failure and transplantation after itraconazole treatment for toenail onychomycosis. J Eur Acad Dermatol Venereol 2005;19:205-7.
152. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van't Wout JW, Stricker BH. Hepatic injury associated with itraconazole. Lancet 1992;340:251-2.
153. Gallardo-Quesada S, Luelmo-Aguilar J. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995;34:589.
154. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29:S50-S54.
155. Bronstein JA, Gros P, Hernandez E, Larroque P, Molinié C. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997;25:1266-7.
156. Crerar-Gilbert A, Boots R, Fraenkel D, MacDonald GA. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care 1999;27:650-2.
157. Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med 1994;96:188-90.
158. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43:53-9.
159. Wallace SJ. A comparative review of the adverse effects of anti-convulsants in children with epilepsy. Drug Saf 1996;15:378-93.
160. Tidwell A, Swims M. Review of the newer antiepileptic drugs. Am J Manag Care 2003;9:253-76.
161. Swann AC. Major system toxicities and side effects of anticon-vulsants. J Clin Psychiatry 2001;62 (Suppl 14):16-21.
162. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22:169-83.
163. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002;87:462-6.
164. Li AM, Nelson EA, Hon EK, et al. Hepatic failure in a child with anti-epileptic hypersensitivity syndrome. J Paediatr Child Health 2005;41:218-20.
165. Licata AL, Louis ED. Anticonvulsant hypersensitivity syndrome. Compr Ther 1996;22:152-5.
166. Hadzić N, Portmann B, Davies ET, Mowat AP, Mieli-Vergani G. Acute liver failure induced by carbamazepine. Arch Dis Child 1990;65:315-7.
167. Bosdure E, Cano A, Roquelaure B, et al. [Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure; in French.] Arch Pediatr 2004;11:10737.
168. Mitchell AA, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S. Adverse drug reactions in children leading to hospital admission. Pediatrics 1988;82:24-9.
169. Powers NG, Carson SH. Idiosyncratic reactions to phenytoin. Clin Pediatr 1987;26:120-4.
170. Overstreet K, Costanza C, Behling C, Hassanin T, Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci 2002;47:1921-5.
171. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001;23:277-83.
172. Onat F, Ozkara C. Adverse effects of new antiepileptic drugs. Drugs Today (Barc) 2004;40:325-42.
173. Verrotti A, Greco R, Latini G, Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Pediatr Endocrinol Metab 2005;18:423-30.
174. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002;40:789-801.
175. Narkewicz MR, Sokol RJ, Beckwith B, Sondheimer J, Silverman A. Liver involvement in Alpers disease. J Pediatr 1991;119: 260-7.
176. Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lücking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 2001;11:757-9.
177. Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000;20:346-8.
178. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997;156:562-4.
179. Fromenty C, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. J Hepatol 1997;26(Suppl 2):43-53.
180. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002;22:195-206.
181. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver disease: a therapeutic challenge for the new millennium. Hepatology 1999;30:1099-104.
182. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26 (Suppl 1):47-51.
183. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391-401.
184. Bagnell PC, Ellenberg HA. Obstructive jaundice due to a chlorinated carbon in breast milk. Can Med Assoc J 1977;117:1047-8.
185. Rasenack R, Müller C, Kleinschmidt M, Rasenack J, Wiedenfeld H. Veno-occlusive disease in a fetus caused by pyrrolizidine alkaloids of food origin. Fetal Diagn Ther 2003;18:223-5.
186. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001;34:595-603.
187. Aithal GP. When is a herb a drug? Eur J Gastroenterol Hepatol 2005;17:391-3.
188. Stickel F, Pöschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003;38:565-8.
189. Stickel F, Baumüller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003;9:62-7.
190. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine and pyrroli-dinophenone types: a synopsis. Ther Drug Monit 2004;26:127-31.
191. Kew MC, Bersohn I, Siew S. Possible hepatotoxicity of cannabis. Lancet 1969;i:578-9.
192. Hochman JS, Brill NQ. Chronic marihuana usage and liver function. Lancet 1971;ii:818-9.
193. Borini P, Guimares RC, Borini SB. Possible hepatotoxicity of chronic marijuana usage. Sao Paulo Med J 2004; 122:110-6.
194. Cooper AD, Niejadlik D, Huston K. Liver disease in nonpar-enteral drug abusers. JAMA 1975;233:964-6.
195. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe hepatic hepatoxicity. J Hepatol 1998;29:394-7.
196. Fidler H, Dhillon A, Gertner D, Burroughs A. Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996;2: 563-6.
197. Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC. Ecstasy induced hepatitis mimicking viral hepatitis. Gut 1995; 36:939-41.
198. Ellis AJ, Wendon JA, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996;38:454-8.
199. Lange-Brock N, Berg T, Müller AR, et al. [Acute liver failure following the use of ecstasy (MDMA); in German.] J Gastroenterol 2002;40:581-6.
200. Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004;41:1062-4.
201. Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal weight loss aids chaso or onshido. Ann Intern Med 2003;139:488-92.
202. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002;136:590-5.
203. Han D, Matsumaru K, Rettori D, Kaplowitz N. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 2004; 67:439-51.
204. Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. Eur J Emerg Med 1998;5:467-9.
205. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
206. Braun M, Fraser GM, Kunin M, Salamon F, Kaspa RT. Mesalamine-induced granulomatous hepatitis. Am J Gastro-enterol 1999;94:1973-4.